Show results for
Refine by
Vascular Endothelial Growth Factor Equipment Supplied In Europe
7 equipment items found
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Avastin is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). With the initial approval in the United States for advanced colorectal cancer in 2004, Avastin became the first anti-angiogenic therapy made widely available for the treatment of patients with an advanced ...
Manufactured by:Newcells Biotech Limited based inNewcastle Upon Tyne, UNITED KINGDOM
RPE characterisation includes: morphology assessment, pigmentation, RPE-specific expression at the protein level (BEST1, TYRP1), the analysis of phagocytosis of photoreceptor outer segments, trans-epithelial resistance (TEER), polarity of apical Pigment Epithelium-Derived Factors (PEDF) and basal vascular endothelial growth ...
Manufactured by:Ikarovec based inNorwich, UNITED KINGDOM
Age-related macular degeneration (AMD) is a painless eye condition that leads to the gradual loss of central vision and is the most common cause of sight loss in the developed world and the third most common globally. Around 600,000 people in the UK currently have sight loss caused by AMD and around 70,000 new cases are diagnosed every year. Macular degeneration develops when the macula (the part ...
Manufactured by:Lonza Group Ltd based inBasel, SWITZERLAND
Culture system containing EBMTM-2 Basal Medium (CC-3156) and EGMTM-2 MV Microvascular Endothelial Cell Growth Medium SingleQuotsTM supplements (CC-4147) required for growth of Microvascular Endothelial ...
Manufactured by:Lonza Group Ltd based inBasel, SWITZERLAND
Culture system containing EBMTM-2 Basal Medium (CC-3156) and EGMTM-2 SingleQuotsTM Supplements (CC-4176) required for growth of Endothelial Cells. Available for immediate ...
Manufactured by:Ikarovec based inNorwich, UNITED KINGDOM
Diabetic macular edema (DME) is the most common cause of sight loss in diabetics. The longer you have diabetes, the greater your chance of developing sight loss. About 90% of people with type 1 diabetes will have some degree of retinopathy after 10 years. For people with type 2 diabetes, the chance of developing retinopathy after 10 years is between 67% and 80%. DME is caused by blood vessels in ...
Manufactured by:Estar Medical UK Ltd based inHarrow, UNITED KINGDOM
Tropocells® PRP system utilizes a patented separator gel technology to isolate the platelets while eliminating the undesirable components such as red blood cells and inflammatory white blood cells. Tropocells PRP reflects the latest technology to accelerate the body’s natural ability to heal itself. Tropocells involves the patient’s blood being extracted and spun to obtain a ...